Veru amends Lincoln Park equity facility to $50M; unveils enobosarm GLP-1 combo plan

VERU INC.

Amended Lincoln Park agreement reduces registered shares from $100M to $50M until $50M sold; only $3.1M sold to date.
Plans to develop enobosarm to augment fat loss and prevent muscle loss in elderly on GLP-1 drugs.
Updated corporate presentation includes enobosarm Phase 2b trial design for sarcopenic obese/overweight patients.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VERU INC. amended the Amendment with Lincoln Park Capital Fund, LLC valued at from $100 million to $50 million (effective 2023-12-13).

Action: amendment
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Value: from $100 million to $50 million
Effective: 2023-12-13

Exact text from the filing

On December 13, 2023, the Company entered into an amendment (the “Amendment”) to the Agreements to reduce the amount of shares of common stock subject to the registration under the Agreements from $100 million to $50 million until the Company has sold at least $50 million of shares of common stock under the Purchase Agreement.

View on SEC.gov

120 material agreements filed in the last 30 days. Browse all material agreements →

VERU INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-294320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.